Patents Assigned to Biocon Limited
-
Patent number: 9101596Abstract: An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z—R2??(Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R1 or R2 is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.Type: GrantFiled: January 24, 2011Date of Patent: August 11, 2015Assignee: BIOCON LIMITEDInventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica Puskas, Nnochiri N. Ekwuribe
-
Patent number: 9102758Abstract: An insulin conjugate is disclosed in which insulin is coupled to a modifying moiety of the formula X—R1—Y-PAG-Z—R2 wherein X, Y, and Z are linking groups, R2 is a capping group, and PAG is a carbon chain that incorporates one or more alkylene glycol moieties.Type: GrantFiled: January 18, 2011Date of Patent: August 11, 2015Assignee: BIOCON LIMITEDInventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica E. Puskas, Nnochiri N. Ekwuribe
-
Patent number: 9090705Abstract: The present invention relates to the preparation of insulin compounds including their analogs or derivatives thereof from their corresponding precursor forms by a one step enzymatic reaction involving the combinatorial and concurrent use of optimal quantities of trypsin and carboxypeptidase B that work synergistically directing the reaction in a controlled manner to avoid production of random undesired byproducts. Particularly, the enzymatic conversion reactions of the instant invention offer advantages of reduction in the number operational steps, higher yield and purity of the desired end products.Type: GrantFiled: September 19, 2008Date of Patent: July 28, 2015Assignee: Biocon LimitedInventors: Partha Hazra, Srikanth Gollarahosahalli Sathyanarayana, Suma Sreenivas, Manjunath Hadavanahalli Shivarudraiah, Kedarnath Nanjund Sastry, Harish Iyer
-
Patent number: 9079921Abstract: The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis.Type: GrantFiled: November 17, 2011Date of Patent: July 14, 2015Assignee: Biocon LimitedInventors: Srinivas Pullela Venkata, Ganesh Ekambaram, Kiran Kumar Kothakonda, Anegondi Sreenivasa Prasad
-
Patent number: 9040723Abstract: The present invention relates to methods of synthesizing oligomeric compounds, and more particularly, to methods of synthesizing oligomer compounds comprising polyethylene glycol moieties. The present invention provides improved methods for synthesizing oligomers comprising polyethylene glycol moieties. Methods according to embodiments of the present invention may utilize reaction conditions that are milder, efficacious than those taught by conventional methods.Type: GrantFiled: August 28, 2008Date of Patent: May 26, 2015Assignee: BIOCON LIMITEDInventors: Reena Vijayaraghavan, Srinivas Pullela Venkata, Chandrashekar Aswathanarayanappa
-
Publication number: 20150118710Abstract: The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the host Pichia pastoris to produce two chain functional glargine secreted directly in the medium. The schematic diagram of how the two chains are made inside the host Pichia pastoris and secretes into the medium.Type: ApplicationFiled: June 6, 2012Publication date: April 30, 2015Applicant: Biocon LimitedInventors: Nagaraj Govindappa, Suma Sreenivas, Komal N. Kanojia, Yogesh Basavaraju, Kedarnath Nanjund Sastry
-
Patent number: 8975041Abstract: The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.Type: GrantFiled: October 26, 2009Date of Patent: March 10, 2015Assignee: Biocon LimitedInventors: Nagaraj Govindappa, Nandini Nataraj, Sanjay Tiwari, Partha Hazra, Mukesh Babuappa Patale, Gokul Jothiraman, Kedarnath Sastry
-
Patent number: 8927256Abstract: The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as Pichia.Type: GrantFiled: February 5, 2009Date of Patent: January 6, 2015Assignee: Biocon LimitedInventors: Sanjay Tiwari, Mukesh Babuappa Patale, Saurabh Garg, Mayank Kumar Garg, Sulekha Joshi, Chittnalli Ramegowda Naveen Kumar, Bimal Kumar, Anuj Goel, Harish Iyer
-
Publication number: 20140275535Abstract: The present invention relates to the stable acid addition salts of Bosentan that are useful for the purification of Bosentan base. In particular, the Bosentan acid addition salt is selected from Bosentan citrate and Bosentan tartrate.Type: ApplicationFiled: December 1, 2011Publication date: September 18, 2014Applicant: Biocon LimitedInventors: Srinivas Pullela Venkata, Kiran Kumar Kothakonda, Shanmughasamy Rajmahendra, Indrajit Chandrasekaran, Mariappan Kaliappan, Rekha Shivappa Mailar
-
Patent number: 8815247Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: GrantFiled: March 13, 2013Date of Patent: August 26, 2014Assignee: Biocon LimitedInventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
-
Patent number: 8802816Abstract: The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as Pichia pastoris. The invention also relates to methods used to clone gene encoding the protein insulin glargine; inserting the related gene in a suitable yeast host; producing culture of the recombinant strain, stimulating expression of the heterologous polypeptide, its secretion and purification post fermentation and related enzymatic conversions.Type: GrantFiled: April 3, 2008Date of Patent: August 12, 2014Assignee: Biocon LimitedInventors: Partha Hazra, Nitesh Dave, Vivekanandan Kannan, Sanjay Tiwari, Anuj Goel, Harish Iyer, Nita Roy, Krishnamurthy Venkatesan, Anoop Vasudevan, Anupama Jagadish, Goldy Sachdev, Mukesh Babuappa Patale
-
Patent number: 8778659Abstract: The disclosure relates to method of reducing O-glycosylation levels of the insulin or insulin analog precursor molecule produced by Pichia sp. The present disclosure provides genetically engineered knock-out strains of methylotrophic yeast including Pichia and especially Pichia pastoris by disruption of Protein mannosyl transferase (PMT) genes and rendering them capable of producing heterologous proteins with reduced glycosylation. Vectors, which comprise coding sequences for PMT1, PMT2, PMT4, PMT5, and PMT6 genes, for transforming methylotrophic yeasts are contemplated by the present disclosure. PMT inactivated strains of this disclosure have been deposited at MTCC, Chandigarh. The strains are PMT1/GS115 (MTCC 5515), PMT4/GS115 (MTCC 5516), PMT5/GS115 (MTCC 5517) and PMT6/GS115 (MTCC 5518).Type: GrantFiled: March 29, 2010Date of Patent: July 15, 2014Assignee: Biocon LimitedInventors: Nagaraj Govindappa, Komal Kanojia, Krishnamurthy Venkatesan, Nitesh Dave, Mukesh Babuappa Patale, Sanjay Tiwari, Kedarnath N. Sastry, Harish Iyer
-
Patent number: 8759290Abstract: The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding motif for action on a GLP-1 receptor and at least one oligomer conjugation site for binding with at least one oligomer, wherein the oligomer includes a polyethylene glycol moiety (PEG), and/or alkyl moiety.Type: GrantFiled: October 18, 2006Date of Patent: June 24, 2014Assignee: Biocon LimitedInventor: Kenneth D. James
-
Patent number: 8754197Abstract: Methods are disclosed for preparing compounds of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. The compounds and or their metabolites can be used to treat or prevent various diseases, particularly inflammatory conditions of the GI tract.Type: GrantFiled: November 19, 2012Date of Patent: June 17, 2014Assignee: Biocon LimitedInventors: Jennifer A. Riggs-Sauthier, Nnochiri N. Ekwuribe
-
Publication number: 20140141467Abstract: The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as Pichia.Type: ApplicationFiled: January 23, 2014Publication date: May 22, 2014Applicant: Biocon LimitedInventors: Sanjay Tiwari, Mukesh Babuappa Patale, Saurabh Garg, Mayank Kumar Garg, Sulekha Joshi, Chittnalli Ramegowda Naveen Kumar, Bimal Kumar, Anuj Goel, Harish Iyer
-
Publication number: 20140031529Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: ApplicationFiled: September 3, 2013Publication date: January 30, 2014Applicants: CENTRO DE INMUNOLOGIA MOLECULAR, BIOCON LIMITEDInventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
-
Publication number: 20140005355Abstract: The present invention discloses a process for the preparation of Caspofungin and its intermediates from Pneumocandin B0.Type: ApplicationFiled: February 18, 2011Publication date: January 2, 2014Applicant: BIOCON LIMITEDInventors: Kiran Kumar Kothakonda, Sandeep Rao Sripathi, Srinivas Pullela Venkata, Lijo George, Anegondi Sreenivasa Prasad
-
Publication number: 20130287802Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Applicant: BIOCON LIMITEDInventors: NAGARAJ GOVINDAPPA, Kedarnath Sastry, Maria Melina Soares
-
Patent number: 8563685Abstract: Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.Type: GrantFiled: October 20, 2009Date of Patent: October 22, 2013Assignee: Biocon LimitedInventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Leo Pavliv, Karen Polowy, Monica Puskas, Nnochiri N. Ekwuribe
-
Patent number: 8524233Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 4, 2008Date of Patent: September 3, 2013Assignee: Biocon Limited & Centro de Immunologia MolecularInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez